Introduction
Worldwide, lung cancer is the most common cancer and leading cause of cancer death. In 2018, 2.09 million people were diagnosed with lung cancer and there were 1.76 million deaths from lung cancer. 1 Non-small-cell lung carcinoma (NSCLC), divided into two major groups by histology: squamous and nonsquamous, is the most common type of lung cancer, accounting for 84% of all lung cancer diagnoses. 2 While tyrosine kinase inhibitors (TKIs) have redefined treatment options for patients with genetic aberrations such as epidermal growth factor (EGFR) and anaplastic lymphoma kinase (ALK), many patients do not harbour these oncogenic drivers. Standard treatment for oncogene-negative patients was cytotoxic chemotherapy but prognosis remains poor and novel treatment approaches are needed.
An improvement in understanding the cancer immunology has enabled the development of immune-checkpoint inhibitors that has dramatically altered the therapeutic landscape of advanced NSCLC. 3 In this review, the evolving landscape of immune-checkpoint inhibitors in the first-line treatment of NSCLC and its future perspectives will be discussed (Figure 1 ). pembrolizumab interrupts the engagement of PD-1 with its ligands. Atezolizumab, avelumab and durvalumab are anti-PD-L1 antibodies which interrupt the binding of PD-L1 to PD-1. The inhibition of PD-L1 to PD-1 results in tumour recognition by cytotoxic T cells. [5] [6] [7] Cytotoxic T-lymphocyte antigen 4 (CTLA-4), expressed on regulatory T cells, competitively binds CD80 and CD86. CTLA-4 activation leads to the downregulation of helper T-cell activity and increases T regulatory immunosuppressive activity. 8, 9 Ipilimumab, a fully human IgG1 anti-CTLA-4 inhibitor interrupts the binding of CTLA-4 to CD80 and CD86.
Immune-checkpoint inhibitors monotherapy in the first-line treatment in advanced NSCLC
The success of immune-checkpoint inhibitors in the pretreated advanced NSCLC when compared with docetaxel led to the approval of nivolumab and atezolizumab regardless of PD-L1 status and pembrolizumab in PD-L1 positive tumours (PD-L1 ⩾ 1%; Table 1 [10] [11] [12] [13] [14] [15] [16] ). This subsequently led to the conduct of multiple studies exploring the role of immune-checkpoint inhibitors in the first-line setting (Table 2) .
First-line pembrolizumab monotherapy
The role of pembrolizumab monotherapy in untreated advanced NSCLC was first explored in a large phase I study, KEYNOTE-001. In the cohort of patients with previously untreated advanced NSCLC, pembrolizumab was reported to show encouraging activity. In patients with tumour-expressing PD-L1 tissue polypeptidespecific antigen (TPS) ⩾ 50%, the objective response rate (ORR) was 66.7% whereas the ORR was 30.8% in patients with PD-L1 between 1 and 49%. Furthermore, reported progressionfree survival (PFS) and overall survival (OS) in tumours with PD-L1 ⩾ 50% was promising. 17, 18 In a phase III study, KEYNOTE-024, patients with advanced NSCLC and a PD-L1 TPS ⩾ 50% were randomized to pembrolizumab for 35 cycles versus platinum-based chemotherapy for four to six cycles. The primary endpoint was met, with a significant improvement in median PFS seen in pembrolizumab versus chemotherapy treated patients and this benefit was evident in all subgroups examined. 19 In an updated analysis, the OS was 30.0 months in the pembrolizumab group versus 14.2 months in the chemotherapy group (Table 2) . About 44% of patients who received chemotherapy crossed over to receive pembrolizumab. When adjusted for crossover, the OS still favoured pembrolizumab [hazard ratio (HR) 0.49, 95% confidence interval (CI) 0.34-0.69]. 20 Grade 3 or more treatment-related adverse events occurred in twice as many patients in the chemotherapy group as in the pembrolizumab group. 19 The results of KEYNOTE-024 led to the US Food and Drug Administration (FDA) approval of pembrolizumab for advanced NSCLC with PD-L1 TPS ⩾ 50%. However, what remained unknown was whether pembrolizumab was effective in patients with lower PD-L1 expression. Thus, a phase III study, KEYNOTE-042, was conducted to address the role of single-agent pembrolizumab in patients with PD-L1 TPS ⩾ 1%.
In this study, patients with advanced NSCLC without EGFR mutations or ALK rearrangement were randomized to receive pembrolizumab or platinum doublet. There were three primary endpoints: OS in patients with a PD-L1 TPS ⩾ 50%, ⩾20% and ⩾1%. The median OS was significantly higher across these three subgroups in patients treated with pembrolizumab versus chemotherapy ( Table 2) . In contrast to KEYNOTE-024, in patients with PD-L1 ⩾ 50%, pembrolizumab treatment was not associated with an improvement in PFS. In a prespecified exploratory analysis of the cohort with PD-L1 expression 1-49%, the OS in patients treated with pembrolizumab or chemotherapy was 13.4 months and 12.1months, respectively. This suggests the benefit seen in the overall population with a PD-L1 expression ⩾ 1% was driven by patients with high PD-L1 expression (>50%). Furthermore, the OS curves crossed, suggesting initial benefit with chemotherapy and subsequently a separate patient group that derived benefit from pembrolizumab. Identifying biomarkers in this group of patients with a PD-L1 TPS 1-49% who obtained benefit from pembrolizumab would therefore be of major interest. Grade 3 or more treatment-related adverse events were more frequent in the chemotherapy arm (Table 2) . 20 Based on the results from KEYNOTE-042, the FDA recently granted approval for pembrolizumab monotherapy for patients with stage III NSCLC who are not candidates for surgical The efficacy of pembrolizumab monotherapy in EGFR-mutant advanced NSCLC was reported recently. In a single-arm phase II study, EGFR TKI-naïve patients with advanced NSCLC with PD-L1 ⩾ 1% were recruited. Enrolment was halted because of lack of efficacy after 11 of 25 planned patients were treated. Despite being enriched for high PD-L1 expression (73% of patients with a PD-L1 ⩾ 50%), the ORR was 9% (1/11). Of the single responder, repeat EGFR mutation testing revealed the original report of EGFR exon 19 deletion to be erroneous, thus the actual ORR in 10 patients was 0%. 21 Of the seven patients receiving subsequent EGFR TKIs, six patients (86%) developed an adverse event attributed to TKI use, with one case of fatal pneumonitis 89 days after commencing erlotinib. It is unknown whether pembrolizumab contributed to the development of pneumonitis but its manifestation raises issues about the potential risks of sequencing with immune-checkpoint inhibitors and EGFR TKIs. Based on this study, pembrolizumab is not an appropriate treatment option for patients with treatment-naïve EGFR-mutant NSCLC expressing PD-L1 and concerns remain regarding the safety of sequencing EGFR TKIs after immune-checkpoint inhibitors.
First-line nivolumab monotherapy
A phase III study, CheckMate 026, explored the efficacy of nivolumab compared with platinumbased chemotherapy as first-line therapy in patients with advanced NSCLC with PD-L1 ⩾ 1%. The primary endpoint was PFS among patients with PD-L1 ⩾ 5%. There was no PFS or OS benefit seen with nivolumab (Table 2) . 22 The results from CheckMate 026 are inconsistent with first-line nivolumab in phase I and II trials. 23 What could possibly account for this? First, the characteristics of patients in both arms of the study are different. The proportion of patients with PD-L1 ⩾ 50% are 47% and 32% in the chemotherapy and nivolumab group, respectively. Second, 43% of patients in the nivolumab arm crossed over to receive subsequent chemotherapy, and 64% of patients who received chemotherapy crossed over to receive immunotherapy. The lower rates of crossover in patients who JL Low, RJ Walsh et al.
journals.sagepub.com/home/tam 9 received nivolumab might have contributed to the lack of OS benefit. In an exploratory analysis, the authors found higher response rates in patients with a high tumour mutational burden (47% versus 28%) and longer PFS. 24, 25 While KEYNOTE-024 established the role for pembrolizumab as first-line treatment for NSCLC with a PD-L1 TPS ⩾ 50%, the results from CheckMate 026 were discordant. The factors explaining the differences in results between KEYNOTE-024 and CheckMate 026 are unknown but might be attributable to differences in patient selection. Patient selection was based on a tumour PD-L1 expression cut-off of 1%. In contrast, a PD-L1 cut-off of 50% using a prospectively validated assay (22C3) was used in KEYNOTE-024.
First-line atezolizumab monotherapy
In the multicohort, single-arm phase II trial (BIRCH), a cohort of patients with chemotherapynaïve advanced NSCLC was treated with first-line atezolizumab. All patients had PD-L1 ⩾ 5% on tumour cells (TCs) or immune cells (ICs) using the SP142 immunohistochemistry assay. The ORR, PFS and OS were 22%, 5.4 months and 23.5 months, respectively. In patients with TC3 (TC PD-L1 ⩾ 50%) or IC3 (IC PD-L1 ⩾ 10%), ORR was 31%. 26 In another multicohort phase II study (FIR), the efficacy and safety of patients with PD-L1 staining on ⩾5% of TCs or PD-L1 staining on ⩾5% of ICs were assessed. The cohort of patients who were chemotherapy naïve or more than 6 months between adjuvant chemotherapy and recurrence, were treated with single-agent atezolizumab, the ORR, PFS and OS were 32%, 5.5 months and 14.4 months, respectively. In patients with TC3 or IC3, the ORR was 43%. 27 A single-arm phase II trial, BF1RST, enrolled patients with PD-L1 unselected, advanced NSCLC, with high levels of blood tumour mutation burden to receive atezolizumab. The ORR in the overall intention-to-treat population was 14.5%. 28 Results based on tumour mutation burden (TMB) status will be discussed in a later section.
Combination first-line immune-checkpoint inhibitor and chemotherapy
Single-agent immune-checkpoint inhibitors have transformed the paradigm of advanced NSCLC in both front line and after failure of platinumcontaining chemotherapy. Despite the improvement, not all patients will benefit from single-agent immune-checkpoint inhibitor with an ORR of 45% versus 27% in PD-L1 50% or more and 1% or more, respectively. [18] [19] [20] Historically, it was thought cytotoxic chemotherapy was immunosuppressive but ample evidence has shown chemotherapy can modulate the immune response against tumours and may increase the efficacy of immune-checkpoint inhibitors. The overall goal of combination immune-checkpoint inhibitor and chemotherapy is to achieve additive or synergistic clinical activity. This objective can be achieved by two major approaches. First, by using chemotherapy to induce immunogenic cell death and second, by using chemotherapy to interfere with the mechanisms used by the tumour to evade immune recognition. [29] [30] [31] [32] This has led to the conduct of studies exploring the role of immune-checkpoint inhibitors and chemotherapy in the first-line treatment of advanced NSCLC.
Pembrolizumab and chemotherapy
In a phase II study (KEYNOTE-021G), patients with nonsquamous histology and without EGFR mutations or ALK rearrangement were randomized to carboplatin-pemetrexed and pembrolizumab or carboplatin-pemetrexed. The study reported an improvement in response rate, PFS and trend towards an improvement in OS (Table 2) . 33, 34 The increased activity seen when combining pembrolizumab with chemotherapy in nonsquamous histology was confirmed in a subsequent phase III study, KEYNOTE-189.
KEYNOTE-189 and KEYNOTE-407 enrolled patients with advanced nonsquamous and squamous NSCLC respectively. KEYNOTE-189 randomized patients to platinum-pemetrexed with or without pembrolizumab, followed by maintenance pemetrexed or pemetrexed/pembrolizumab. There was clear OS and PFS benefit with the addition of pembrolizumab to chemotherapy. OS benefit was seen across all patient subgroups including a cohort without PD-L1 expression. It should be noted that the degree of benefit with combination therapy was associated with PD-L1 status with a larger benefit seen with tumours with a higher PD-L1 expression. There was also PFS benefit in most subgroups except in patients aged > 65 years or PD-L1 TPS < 1%. Likewise, in KEYNOTE-407, both OS and PFS were improved in the overall patient population, as well as all subgroups. With the caveat of crosstrial comparisons, in these studies, the response rates with the combination therapy were higher than seen in monotherapy (47.6% in KEYNOTE-189 and 57.9% in KEYNOTE-407). Toxicities were generally manageable and rates of all-grade toxicities and grade 3-5 toxicities were similar in both arms, with expected rates of immune-related adverse effects in the immunotherapy arms (Table 2 ; Figure 3) . 35, 36 Based on the results from KEYNOTE-189 and KEYNOTE-407, the FDA recently approved pembrolizumab in combination with chemotherapy in previously untreated advanced nonsquamous and squamous NSCLC.
Currently, we believe that in patients without EGFR mutations or ALK rearrangement and with PD-L1 = 1-49%, combination chemotherapy and pembrolizumab is the best option in the treatment of first-line advanced NSCLC ( Figure  2 ) and single-agent pembrolizumab perhaps considered in patients who are unfit or unwilling to receive platinum-based chemotherapy. For patients without EGFR mutations or ALK rearrangement with PD-L1 ⩾ 50%, treatment options include either single-agent pembrolizumab or the combination of chemotherapy and pembrolizumab. It should be noted no study has compared chemotherapy plus pembrolizumab versus pembrolizumab monotherapy. In the absence of direct comparative data for these patients, we believe that single-agent pembrolizumab should be considered for the majority of patients, which would allow the option of using a platinum-based doublet in the second-line setting, whereas first-line combination chemotherapy and pembrolizumab should be considered in patients with symptomatic or rapidly progressive disease. In such patients, early progression with single-agent pembrolizumab may lead to a decline in performance status, precluding a second-line platinum doublet. Studies comparing single-agent pembrolizumab with chemotherapy and pembrolizumab in patients with NSCLC PD-L1 ⩾ 50% may provide further clarity on the optimal treatment approach.
Nivolumab and chemotherapy
CheckMate 227 is a multipart phase III trial evaluating different nivolumab-based regimens versus chemotherapy in distinct patient populations (PD-L1 < 1% and PD-L1 ⩾ 1%). Patients with PD-L1 < 1% were randomized to platinum-based chemotherapy alone, platinum-based chemotherapy Subsequent investigations revealed a non-small-cell lung cancer, adenocarcinoma histologic subtype that was wildtype EGFR, and negative for ALK and ROS1 rearrangements. PD-L1 tumour proportion score using 22C3 immunohistochemistry was 30%. A CT PET was reported to show an FDG avid left lower-lobe pulmonary mass, pulmonary nodules, hepatic and bony lesions, and a large pericardial effusion. Carboplatin, pemetrexed and pembrolizumab were subsequently initiated. with nivolumab or nivolumab with ipilimumab.
Patients with PD-L1 ⩾ 1% were randomized to platinum-based chemotherapy alone, nivolumab alone or nivolumab with ipilimumab. 37 Part 1 of the CheckMate 227 evaluated PFS and OS of combination immune-checkpoint inhibitor versus chemotherapy. In patients with PD-L1 < 1%, PFS was improved with nivolumab and chemotherapy combination versus chemotherapy alone (HR 0.74, 95% CI 0.58-0.94). Among histological subgroups, benefit was more pronounced in nonsquamous NSCLC (HR = 0.68) relative to squamous NSCLC (HR = 0.92). The rates of treatment-related adverse events leading to discontinuation were 13% and 14%, respectively. 37, 38 The ongoing part 2 CheckMate 227 will be evaluating OS in PD-L1% unselected patients receiving chemotherapy with or without the addition of nivolumab.
Atezolizumab and chemotherapy
Multiple phase III studies examining the role of combination atezolizumab with chemotherapy in the first-line treatment of advanced NSCLC have been conducted (Table 2) . IMpower 150 randomized patients with advanced, untreated nonsquamous NSCLC to carboplatin and paclitaxel combined with atezolizumab (ACP), atezolizumab plus bevacizumab (ABCP) or bevacizumab (BCP). ABCP demonstrated improved and OS over BCP. Based on these results, ABCP has been approved by the US FDA and the European Medicines Agency (EMA) for first-line treatment of patients with NSCLC without EGFR mutation or ALK rearrangement. 39 Outcomes in a subset of patients harbouring EGFR mutations or ALK rearrangement (14% of the study population) were also analysed. In this molecularly defined group treated with ABCP versus BCP, the PFS and OS was 9.7 months versus 6.1 months (HR 0.59, 95% CI 0.37-0.94) and not reached versus 17.5 months (HR 0.54, 95% CI 0.29-1.03), respectively. 39, 40 IMpower 150 is the first study to demonstrate an improvement in outcomes in patients with EGFR mutations or ALK rearrangement treated with the combination of chemotherapy, BCP and atezolizumab. Based on these findings, the EMA has approved the use of ABCP in the treatment of patients with NSCLC harbouring EGFR mutations or ALK translocation after failure of appropriate targeted therapies.
IMpower 130 evaluated the addition of atezolizumab to carboplatin and nab-paclitaxel in patients with previously untreated nonsquamous NSCLC. There was a PFS and OS benefit seen in all PD-L1 subgroups in patients treated with atezolizumab, carboplatin and nab-paclitaxel. In contrast to IMpower 150, in this study, where BCP was not part of the treatment, there was no PFS and OS benefit seen in the subset of patients with EGFR/ALK genomic alterations. Nabpaclitaxel was chosen because it does not require steroid premedication which may affect response to immune-checkpoint inhibitors. 41 In IMpower 132, patients with advanced nonsquamous NSCLC were randomized to cisplatin or carboplatin plus pemetrexed and atezolizumab followed by maintenance pemetrexed and atezolizumab or to platinum/pemetrexed followed by maintenance pemetrexed. There was a significant PFS benefit and a nonsignificant trend towards an improvement in OS seen. 42 IMpower 131 was designed to evaluate the addition of atezolizumab to carboplatin with paclitaxel/nab-paclitaxel in previously untreated, PD-L1 unselected squamous NSCLC. While there is a PFS benefit, the interim OS result was not significantly different with the addition of atezolizumab (Table 2) . 43 
Combination first-line immune-checkpoint inhibitor and immune-checkpoint inhibitor
Dual immune-checkpoint blockade has also shown promise. PD-1 and CTLA-4 modulates the immune system through distinct, complementary mechanisms and enhances antitumour activity. 44 
Nivolumab and ipilimumab
The phase I CheckMate 012 trial combined nivolumab with ipilimumab and found encouraging efficacy with a tolerable safety profile. 45 The phase II CheckMate 568 trial confirmed this and found that a TMB ⩾ 10 mutations/megabase was associated with response, irrespective of tumour PD-L1 expression. 46 Part 1 of CheckMate 227 had two coprimary endpoints: to evaluate PFS with nivolumab and ipilimumab versus chemotherapy based on TMB status with a cut-off of ⩾10 mutations/megabase as determined from CheckMate 568 and to look at OS based on PD-L1 expression level. 37 Of note, there was no association between TMB and PD-L1 expression, suggesting TMB is an independent biomarker predicting benefit from nivolumab and ipilimumab, separate from PD-L1 status (Table 2) . 37 50 The safety and tolerability of durvalumab alone or in combination with tremelimumab were consistent with previously reported studies.
NEPTUNE is a phase III study that randomized patients of any PD-L1 status to durvalumab and tremelimumab versus chemotherapy, 51 and POSEIDON randomized patients to platinumbased doublets alone, durvalumab and chemotherapy versus durvalumab/tremelimumab and chemotherapy. 52 Both studies are ongoing and results may provide further clarity on the role of durvalumab and tremelimumab in the first-line setting. (Table 3 ).
Challenges and future directions in first-line treatment of NSCLC
The superiority chemotherapy combined with an immune-checkpoint inhibitor versus chemotherapy in the first-line setting has provided greater therapeutic options but has simultaneously created some uncertainty on what is the optimal approach in patients with PD-L1 expression of at least 50% where either single-agent pembrolizumab or combination chemotherapy with an immune-checkpoint inhibitor are both superior to chemotherapy. As discussed earlier, pembrolizumab monotherapy can be considered for most patients, as this would enable the use a platinumbased doublet in the second-line setting and combination chemotherapy and pembrolizumab should be considered in patients with symptomatic or rapidly progressive disease. Further research in identifying biomarkers that predict response and allow selection for monotherapy versus combination therapy is required. 53, 54 Another challenge involves the issue of treatment after first-line therapy. In patients who have progressed after treatment with an immune-checkpoint inhibitor, standard treatment would be either a platinum-based doublet if the patient was chemotherapy naïve, or if they have received platinum-based chemotherapy with an immunecheckpoint inhibitor, second-line chemotherapy, which would be docetaxel with or without nintedanib 11 or ramucirumab 10 and Titanium silicate (TS)-1. 55 It should be noted in these phase III trials in the pretreated setting, none of the patients have received a prior immune-checkpoint inhibitor. The benefit of immune-checkpoint inhibitors in patients who have progressed after first-line immune-checkpoint-inhibitor treatment represents an unmet need with research, focusing on understanding the mechanisms of resistance [56] [57] [58] and novel combination immunotherapy studies targeting the tumour microenvironment, increasing costimulatory signals and T-cell priming being areas of major therapeutic interest. [59] [60] [61] While responses have been observed in patients who were rechallenged in the pretreated setting, 62 in patients who have progressed several months or years after the last dose of first-line immunecheckpoint inhibitor, the role of rechallenge with immune-checkpoint inhibitor either as monotherapy or in combination with chemotherapy is unknown.
The management approach of patients treated with a first-line PD-1 or PD-L1 inhibitor and have developed disease progression in one or two sites is also unknown. In the pretreated setting, a retrospective study reported local therapy to the sites of progression with radiofrequency ablation, radiotherapy, or surgery with continuation of systemic therapy with immune-checkpoint inhibitor may be effective, with a 2-year survival rate of 92%. 63 It should be noted that data supporting this approach is scant and systemic therapy is still standard. Further studies examining the management of oligo-progression in patients with advanced NSCLC treated with first-line immunecheckpoint inhibitors should be explored.
The use of PD-1 and PD-L1 inhibitors in patients with NSCLC harbouring EGFR mutations or ALK rearrangement after progression with standard targeted therapy remains a challenge for several reasons. First, EGFR-mutant and ALK-rearranged NSCLC are associated with a lower TMB and an uninflamed and an immunosuppressive tumour microenvironment; factors Currently, PD-L1 expression using immunohistochemistry is the only approved biomarker in the first-line setting and its expression plays an important role in the selection of treatment for patients with EGFR-/ALK-negative advanced NSCLC. Pembrolizumab monotherapy was initially approved with a tumour PD-L1 expression ⩾ 50% 18 and was subsequently approved for a PD-L1 expression ⩾ 1%, based on the results of KEYNOTE-042. 20 In KEYNOTE-042, the benefit of pembrolizumab appears to be greater with increasing PD-L1 expression with the HR for OS 0.69, 0.77 and 0.81 for PD-L1 cut-offs of ⩾50%, ⩾20% and ⩾1%, respectively. Furthermore, in KEYNOTE-042, exploratory analysis found no survival benefit in the subgroup with PD-L1 expression 1-49%, suggesting the benefit seen in the population with PD-L1⩾1% was carried by the cohort expressing ⩾50% expression. The observation of a higher PD-L1 expression being associated with a greater magnitude of benefit was also seen in studies of combination and pembrolizumab, 35, 36 as well as in the second-line studies. [12] [13] [14] [15] [16] Based on these data, in patients with a PD-L1 expression ⩾ 50%, we recommend singleagent pembrolizumab and combination chemotherapy and pembrolizumab in selected cases such as symptomatic or rapidly progressive disease. In patients with PD-L1 1-49%, we suggest chemotherapy and pembrolizumab should be standard and pembrolizumab monotherapy perhaps considered in patients unfit for, or who decline, chemotherapy. In patients with a PD-L1 expression < 1%, chemotherapy and pembrolizumab is recommended.
Although not yet standard clinical practice, TMB as a predictive marker is gaining traction. TMB has been shown associated with improved outcomes in patients with pretreated NSCLC treated with pembrolizumab 71 atezolizumab 72 and ACB and with nivolumab in the first-line setting. 23 In the BF1RST study, a prospective study evaluating the clinical utility of blood TMB as a predictive biomarker for first-line ACB, in patients with high (⩾16 mutations/megabase) versus low (<16 mutations/megabase) blood TMB, the ORR was 28.6% and 4.4%, respectively, the PFS was 4.6 months and 3.7 months, respectively (HR 0.66, 90% CI 0.42-1.02) and the OS was not estimable versus 13.1 months, respectively (HR 0.77, 90% CI, 0.41-1.43). 73 Based on these promising results, the BFAST, a randomized phase III study [ClinicalTrials.gov identifier: NCT03178552], is ongoing to confirm these findings. With combination therapy, nivolumab/ ipilimumab 46 and durvalumab/tremelimumab 49 was associated with improved outcomes versus chemotherapy in patients with high TMB. Despite the emerging promising data, TMB as a predictive marker for combination CTLA-4/ PD-1 inhibition is currently not part of routine clinical practice, as this combination has not been shown to improve OS; 46, 47 but it has been suggested as an optional treatment regimen for patients with NSCLC with a high TMB. 74 Although challenges exist in the use of TMB in routine practice, such as cost of TMB testing, high tumour DNA requirements and long turnaround time, 75 these potential barriers are being addressed with the rapid technological advances in next-generation sequencing (NGS), the potential utility of plasma TMB 73 and the increasing affordability of NGS, to enable the use of TMB in routine clinical practice. 76 A subset of patients, however, do not benefit from single immune-checkpoint inhibition in the firstline setting, with some patients experiencing early progression in KEYNOTE-024, KEYNOTE-042 and CheckMate-026. Much work remains to identify other, more accurate predictive biomarkers that will allow better patient selection, even among patients with high PD-L1 expression.
With regards to immune-related toxicities, while any organ or tissue may potentially be involved, some immune-related adverse events (irAEs) occur much more commonly than others ( Figure  3 ). Hypothyroidism and hyperthyroidism occur frequently (6-12% and 3-7%, respectively) but most are low-grade adverse events. The incidence of grade 3 or more adverse events is highest for pneumonitis (1-3%). The incidence of irAEs is similar in single-agent immune-checkpoint inhibitor and immune-checkpoint inhibitor/chemotherapy combination (22-29%).
Future research should focus on the management of irAEs, attempting to understand why some patients respond better, increasing the response rates to immune-checkpoint inhibitors and lastly, identifying other pathways to target to improve clinical outcomes. Selected ongoing phase III immune-checkpoint inhibitor trials for first-line treatment of advanced NSCLC are summarized in Table 3 .
Conclusion
Treatment of advanced NSCLC with immunecheckpoint inhibitors has evolved over recent years.
In the second-line setting, treatment options have previously included docetaxel, with or without ramucirumab, an antivascular endothelial growth factor receptor-2 antibody 10 or nintedanib, 11 an oral angiokinase inhibitor. In 2015, the FDA approved nivolumab for use in pretreated advanced NSCLC based on the results of two phase III studies, CheckMate 017 and CheckMate 057. 12, 13 In these studies, nivolumab was superior to secondline docetaxel in terms of response rate (RR) and OS for squamous cell and nonsquamous histology, respectively. Subsequently, pembrolizumab and atezolizumab were also approved for use in patients with advanced NSCLC who have progressed on Table 1 ). Avelumab, in contrast, did not show any OS benefit over docetaxel in the overall population in JAVELIN Lung 200.
Subsequent research, outlined in the review above, has established a role for immune-checkpoint inhibitors in first-line treatment of patients with advanced NSCLC expressing PD-L1 without EGFR or ALK aberrations, either as a monotherapy or in combination with chemotherapy. In patients with PD-L1⩾ 50%, options are either single-agent pembrolizumab or the combination of chemotherapy and pembrolizumab; whereas for patients with PD-L1 1-49%, chemotherapy and pembrolizumab should be considered the best option and pembrolizumab monotherapy is an acceptable option for patients who are unfit or unwilling to receive platinum-based chemotherapy ( Figure 4 ). Multiple studies have also shown chemotherapy with atezolizumab, as well as carboplatin/paclitaxel/ABCP, is active in the first-line setting. When compared with cytotoxic chemotherapy, the use of single-agent immune-checkpoint inhibitors is associated with less toxicities and with combination chemotherapy and immunecheckpoint inhibitor, side effects were higher but tolerable. Ongoing major areas of research include the identification of other biomarkers beyond PD-L1 expression to select patients for combination therapy or immune-checkpoint inhibitor monotherapy, characterization of mechanisms of resistance and determining treatment strategies to overcome resistance and optimise efficacy.
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